10月 2026
scholar.google.com.pr
全球排名
- -
國家/地區排名
- -
同類排名
- -
顯示 Similarweb 的估計資料。
透過連接你的 GA4 公開驗證你網站的指標
反映您的成功
連接 Google Analytics,認證您網站的流量和參與度指標
跳出率
75.55%
每次訪問頁數
1.89
平均訪問時長
00:00:36
- 公司介紹
- - -
- 行業
- - -
scholar.google.com.pr 的前十大競爭對手
在 10月 2026,系統根據關鍵字流量、受眾定位與市場重疊率與 scholar.google.com.pr 的相似程度,排名出 scholar.google.com.pr 等前 10 名網站。
sciencedirect is the world's leading source for scientific, technical, and medical research. explore journals, books and articles.
跳出率
31.28%
每次訪問頁數
6.01
平均訪問時長
00:07:55
Explore options for your family: the YouTube Kids app or a parent supervised account for older kids & teens on YouTube, all with built-in protections.
- 公司介紹
- YouTube
跳出率
23.61%
每次訪問頁數
11.07
平均訪問時長
00:18:45
相似度評分
86%academia.edu is a place to share and follow research.
- 公司介紹
- Academia
跳出率
61.51%
每次訪問頁數
2.35
平均訪問時長
00:01:41
相似度評分
80%Access 160+ million publication pages and connect with 25+ million researchers. Join for free and gain visibility by uploading your research.
跳出率
46.91%
每次訪問頁數
3.59
平均訪問時長
00:03:06
We perform a behavioral experiment of karma, a class of mechanisms for repeated resource allocation with attractive fairness and efficiency properties, in theory. Individuals in these mechanisms bid non-tradable credits that flow from resource consumers to yielders. Human subjects recruited on Amazon MTurk are repeatedly and randomly paired to bid karma according to time-varying individual urgency to acquire resources. Treatments varied in the urgency process (frequent moderate versus sporadic high urgency) and the richness of the bidding scheme (binary versus full range). Benchmarked against random allocation, karma achieves an (almost) Pareto improvement, despite subjects deviating from the theoretically optimal Nash bidding policy: maximum improvement is attained by subjects deviating by up to one karma bid unit on average, and positive improvement with deviations of up to 3-4 units. These findings hold across all treatments, among which no significant differences are found, with the exception of the sporadic high urgency process with binary bidding being (weakly) favorable. They offer behaviorally robust lower bounds for karma's expected performance in human populations and guide its future implementation.
- 公司介紹
- - -
- 行業
- - -
跳出率
39.23%
每次訪問頁數
3.17
平均訪問時長
00:04:08
相似度評分
73%indexingmethod_automated - Search Results - PubMed
- 公司介紹
- - -
- 行業
- - -
全球排名
- -
國家/地區排名
- -
同類排名
- -
跳出率
- -
每次訪問頁數
- -
平均訪問時長
- -
the world’s largest collection of open access research papers
- 公司介紹
- - -
- 行業
- - -
跳出率
26.98%
每次訪問頁數
5.13
平均訪問時長
00:04:27
相似度評分
65%Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. Methods In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. Results A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. Conclusions A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 mont
- 公司介紹
- - -
- 行業
- - -
跳出率
24.78%
每次訪問頁數
3.71
平均訪問時長
00:01:07
Learn more about our institutional models for librarians and the benefits for researchers.
- 公司介紹
- PLOS
跳出率
61.54%
每次訪問頁數
1.75
平均訪問時長
00:01:42
相似度評分
61%DOAJ is a unique and extensive index of diverse open access journals from around the world, driven by a growing community, committed to ensuring quality content is freely available online for everyone.
- 公司介紹
- - -
- 行業
- - -
跳出率
19.35%
每次訪問頁數
4.43
平均訪問時長
00:01:51
相似度評分
59%scholar.google.com.pr 在 10月 2026的前 5 大競爭對手是:sciencedirect.com、youtube.com、academia.edu、researchgate.net 等。
根據 Similarweb 月造訪量數據,scholar.google.com.pr 在 10月 2026 的主要競爭對手為 sciencedirect.com。與 scholar.google.com.pr 相似度排名第二的網站是 youtube.com,緊隨其後位居前三的是 academia.edu。
在 10月 2026,researchgate.net 被評為與 scholar.google.com.pr 相似度第四高的網站,arxiv.org 則位居第五。
前十名榜單中的其他五家競爭對手分別是 pubmed.ncbi.nlm.nih.gov、core.ac.uk、scienceopen.com、plos.org 和 doaj.org。
